Preferred Label : Tepoditamab;
NCIt synonyms : Anti-CLEC12A x CD3 Bispecific Antibody MCLA117; Anti-CLEC12A/Anti-CD3 Bispecific Antibody MCLA117; Bispecific Antibody MCLA-117; Immunoglobulin G1, Bispecific, Anti-(C-type lectin CLEC12A and CD3 Antigen) (Human
Monoclonal MCLA-117 Gamma1-chain), Disulfide with Human Monoclonal MCLA-117 Kappa-chain,
Dimer;
NCIt definition : An immunoglobulin G1 (IgG1) bispecific human monoclonal antibody against human CD3,
a T-cell surface antigen, and human C-type lectin domain family 12 member A (CLEC12A),
a tumor-associated antigen (TAA) overexpressed on certain tumor cells, with potential
antineoplastic activity. Upon administration, tepoditamab binds to both CD3 on T-cells
and CLEC12A expressed on malignant cells, such as myeloid blasts, atypical progenitor
cells and leukemic stem cells (LSCs). This results in the cross-linking of T-cells
with tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against
CLEC12A-expressing tumor cells. CLEC12A, a myeloid differentiation antigen and member
of the C-type lectin/C-type lectin-like domain (CTL/CTLD) superfamily, is overexpressed
on myeloid leukemia cells, but not on normal early hematopoietic progenitors, including
hematopoietic stem cells (HSCs).;
UNII : LK0H7J2V3C;
CAS number : 2044679-53-8;
Molecule name : MCLA 117; MCLA-117;
NCI Metathesaurus CUI : CL550807;
Origin ID : C148141;
UMLS CUI : C5235402;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
